TABLE 4.
Rates of patients switching or discontinuing mepolizumab treatment in the pandemic period
| All | Belgium | Spain | France | Croatia | Italy | Lithuania | The Netherlands | Portugal | Slovenia | Turkey | |
| Patients | 241 | 15 | 26 | 39 | 22 | 32 | 15 | 48 | 4 | 2 | 38 |
| Patients who continued using mepolizumab at follow-up | 219 (91) | 14 (93) | 23 (88) | 36 (92) | 21 (95) | 31 (97) | 14 (93) | 42 (88) | 38 (100) | ||
| Patients who stopped all biological therapy during follow-up | 13 (5) | 1 (7) | 3 (12) | 0 (0) | 1 (5) | 1 (3) | 1 (7) | 6 (12) | 0 (0) | ||
| Patients who switched to another biologic during follow-up | 3 (1) | 0 (0) | 0 (0) | 3 (8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Omalizumab | 0 | 0 | |||||||||
| Reslizumab | 0 | 0 | |||||||||
| Benralizumab | 1 | 1 | |||||||||
| Dupilumab | 2 | 2 | |||||||||
| Months of mepolizumab therapy in patients who stopped or switched during follow-up | # | 5.5 (5.5–5.5) |
3.8 (2–4.8) |
8.8 (8–9.4) |
11.7 (11.7–11.7) |
2.7 (2.7–2.7) |
2.8 (2.8–2.8) |
5.3 (2–6) |
Data are presented as n, n (%) or median (interquartile range). #: not calculable from medians extracted.